Abstract: Skeletal muscle mass plays a vital role in locomotion, whole-body metabolic health, and is a positive predictor of longevity. It is well established the mammalian target of rapamycin (mTOR) is a central regulator of skeletal muscle protein turnover. The pursuit to find novel nutrient compounds or functional food sources that possess the ability to activate mTOR and promote skeletal muscle protein accretion has been on going. Over the last decade, a key role has been proposed for the phospholipid phosphatidic acid (PA) in mTOR activation. Mechanical load-induced (i.e., resistance exercise) intramuscular PA can directly bind to and activate mTOR. In addition, PA provided exogenously in cell culture heightens mTOR activity, albeit indirectly. Thus, endogenously generated PA and exogenous provision of PA appear to act through distinct mechanisms that converge on mTOR and, potentially, may amplify muscle protein synthesis. In support of this notion, limited evidence from humans suggests that resistance exercise training combined with oral supplemental PA enhances strength gains and muscle hypertrophy. However, the precise mechanisms underpinning the augmented muscle remodelling response with supplemental PA remain elusive. In this review, we will critically examine available evidence from cell cultures and animal and human experimental models to provide an overview of the mechanisms through which endogenous and exogenous PA may act to promote muscle anabolism, and discuss the potential for PA as a therapeutic tool to maintain or restore skeletal muscle mass in the context of ageing and disease.
Introduction
Skeletal muscle mass is involved in myriad critical metabolic processes, comprises ϳ40% of total body mass, and is indispensable for locomotory activities of daily living and preventing functional decline (Catoire and Kersten 2015; Janssen et al. 2002; Landi et al. 2012) . With a daily turnover rate of ϳ1%-2% in healthy individuals, skeletal muscle proteins are continually synthesized and degraded (Biolo et al. 1995a ). The algebraic difference between muscle protein synthesis (MPS or anabolism), and muscle protein breakdown (MPB or catabolism) is termed the net protein balance (NPB) (Phillips 2014) . Prolonged periods of a positive NPB, where MPS rates chronically exceed those of MPB, yield skeletal muscle protein accretion or hypertrophy (Tipton et al. 1999) . In contrast, periods of a negative NPB, where MPB rates chronically exceed those of MPS, will lead to muscle protein depletion, manifesting as muscle atrophy (Biolo et al. 1995b) . The importance of the main-tenance of muscle mass and function is best highlighted by a number of epidemiological studies linking these facets to allcause morbidity and mortality (Bunout et al. 2011; Landi et al. 2012; Newman et al. 2006) . Despite the strong association of ageand disease-related muscle wasting with mortality, a unifying mechanism to explain this link has yet to be put forward. Hence, the causality of the muscle wasting-death association, even though biologically plausible, is widely unknown.
On this basis, it is not surprising that ageing and a number of highly prevalent diseases are associated with skeletal muscle wasting. For example, the age-related loss in muscle mass and strength (now termed sarcopenia and dynapenia, respectively) is associated with impaired functional capacity, and heightened risk of falls, fracture, disability, and metabolic disease(s) (Atkins et al. 2014; Baumgartner et al. 1998; Park et al. 2006) . Ultimately, sarcopenia and associated comorbidities diminish quality of life and are closely linked to greater mortality risk (Dominguez and Barbagallo 2007; Janssen and Ross 2005; Landi et al. 2012; Newman et al. 2006) . Besides the slow and insipid loss of muscle mass in ageing, multiple diseased-states increasing in prevalence as a result of ageing, including cancers (Fearon et al. 2012) , rheumatoid arthritis, osteoarthritis (Summers et al. 2008) , chronic obstructive pulmonary disease (COPD) (Wüst and Degens 2007) , heart failure (Fülster et al. 2013) , and sedentary behaviours (Gianoudis et al. 2015) , also compromise muscle mass and function. Therefore, augmentation, or at the very least, maintenance of skeletal muscle mass across the lifespan is critical to offset the progression of disability and disease, thereby closing the ever-expanding gap between healthy life expectancy and average life expectancy in developed nations (Murray et al. 2013) . To date, the most effective means of increasing skeletal muscle mass, strength, or offsetting sarcopenia and dynapenia in ageing and disease, remains resistancetype exercise combined with consumption of adequate proteinbased nutrition (Cermak et al. 2012; Constantin et al. 2013; Tieland et al. 2012) . The robust stimulation of MPS in healthy young individuals in response to these combined anabolic stimuli is well defined, and results in muscle hypertrophy (Mitchell et al. 2012; Tipton et al. 1999) . However, the natural muscle anabolic response to these stimuli is somewhat blunted in older individuals (Cuthbertson et al. 2005; Kumar et al. 2009; Moore et al. 2015) . This so-called "anabolic resistance" to protein-based nutrition and resistance exercise appears to be an important factor in the dysregulation of muscle protein turnover in old age and may underpin the progression of sarcopenia (Fiatarone et al. 1994; Yang et al. 2012a Yang et al. , 2012b . Globally, an ageing trend is observed. Currently 10 million people are aged 65 years and over in the United Kingdom alone. This number is expected to almost double by the year 2050, implicating that 1 in 3 people will be aged 65 years and over (House of Commons Library Research 2010) . Thus, the rapidly expanding ageing demographic in developed nations necessitates the discovery of targeted interventions to counteract the age-and diseaserelated skeletal muscle loss.
During recent years, the pursuit to find novel nutrient compounds or functional food sources with the potential to restore healthy muscle anabolic responsiveness, negate muscle catabolic processes, and alleviate age-and disease-induced muscle atrophy has been on going. Such nutrient compounds with added extra health benefits (in addition to the basic nutritional value found in foods) are often referred to as "nutraceuticals". One purported nutraceutical that has garnered recent attention is phosphatidic acid (PA). PA is a phospholipid consisting of a glycerol backbone with 2 fatty acid chains and a phosphate group. It is found, though in small quantities, in all cell membranes (Xu et al. 2004 ) and can be synthesised endogenously or supplemented exogenously (Joy et al. 2014) . PA is present in very low concentrations in mammalian cell membranes, typically <5% of the concentration of phosphatidylcholine (PC) (Buckland and Wilton 2000) ; a glycerophospholipid accounting for ϳ50% of total cellular phospholipids (van Meer and de Kroon 2011). While quantitatively a minor component of cellular phospholipids, PA forms the backbone on which the syntheses of other phospholipid species are based. Various enzymes contribute to the endogenous synthesis of PA. For example, phospholipase D (PLD) catalyses the cleavage of the phosphodiester bond on PC, the hydrolysis of which forms PA and choline (Exton 1999) . PA is also commonly synthesised from glycerol 3-phosphate (G3P) and newly synthesized fatty acids (FAs). G3P is acylated twice by distinct acyltransferases -the last step being catalysed by a lysophosphatidic acid acyltransferase (LPAAT). (Wang et al. 2006) . The acyl-CoA needed for the acylation of G3P comes from both dietary FAs and newly synthesized palmitic acid, which is catalysed by fatty acid synthase. Thus, the generation of PA via the LPAAT pathway involves nutrient input from glucose, dietary FAs, and de novo FA synthesis. Finally, PA can be generated from stored triglycerides, which are deacylated to diacylglycerol (DAG) and phosphorylation in an ATP-dependent manner through diacylglycerol kinase (Foster 2007; Hornberger 2011) . Conversely, PA can also be degraded for use in the formation of several phospholipids. The phosphate group on PA can be hydrolysed to form DAG via phosphatidic acid phosphatase (Carman and Han 2006) , or lysophosphatidic acid (LPA) via phospholipase A (PLA) (Aoki et al. 2007 ). Thus, it is clear that PA plays a central role in regulating multiple biological effects in mammalian cells. The purpose of this review is to critically summarise available evidence from cell culture and pre-clinical and human studies to gauge whether endogenous PA production and/or exogenous provision offers a novel solution to promoting skeletal muscle anabolism in the context of health, ageing, and disease.
Exercise-induced endogenous PA
Resistance training promotes skeletal muscle hypertrophy, albeit with substantial intra-individual variability, in both young and old individuals (Mayhew et al. 2009; Mitchell et al. 2012 ), whereas muscle unloading (i.e., immobilization or disuse) results in muscle atrophy (Breen et al. 2013; Drummond et al. 2012 ). The principle mechanism through which mechanical loading stimulates muscle anabolism is thought to hinge on the mechanistic target of rapamycin (mTOR) protein kinase complexes, consisting of complex 1 (mTORC1) and complex 2 (mTORC2). Complexes 1 and 2 are similar in that they both contain mTOR and G protein ␤-subunit-like protein, but are different in that mTORC1 contains raptor (regulatory associated protein of mTOR), making this complex rapamycin sensitive, whilst mTORC2 contains rictor (rapamycin insensitive companion of mTOR), rendering this complex rapamycin insensitive (Goodman 2014) . Rapamycin has been shown to inhibit mTORC1 activity by forming a complex with FK506-binding protein 12 (FKBP12) to bind mTORC1 at the FKB12 rapamycinbinding (FRB) domain (Sehgal 2003) . As such, mTORC1 is the rapamycin-sensitive kinase involved in the regulation of MPS and skeletal muscle mass (Hornberger 2011) . Signalling through the mTORC2 is complex and poorly understood, but does not appear to be inhibited by rapamycin and therefore is unlikely to contribute directly to cell growth (Drummond et al. 2009 ). In response to mechanical loading, activation of mTORC1 results in the phosphorylation of ribosomal S6 kinaseu 1 (p70S6K) and eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) (Anthony et al. 2001; Burd et al. 2009 ). The phosphorylation status of these protein substrates of mTORC1 are often used as a surrogate for mTOR activation, and are associated with enhanced protein translational efficiency and consequently superior rates of MPS (Anthony et al. 2001 ). However, whilst the effect of mechanical loading on the activation of mTORC1 substrates regulating mRNA translation are fairly well defined, considerably less is known about the proximal, upstream events that coordinate mechanical load-induced mTORC1 activation in the first instance.
Initial investigations suggested a possible role for the calcineurin/ nuclear factor-activated T-cells (NFAT) pathway in the hypertrophic response to mechanical loading. Mechanical stimulation increases intracellular calcium levels, activating the protein phosphate calcineurin, which translocates NFAT to the nucleus, thereby promoting an increase in mRNA transcription and hypertrophy (Rommel et al. 2001) . However, an elegant study by Bodine and colleagues, in which rats were administered the calcineurin inhibitor cyclosporin A, failed to show any involvement of the calcineurin NFAT/pathway in hypertrophy (Bodine et al. 2001a ). Consequently, the canonical phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) pathway was proposed as a likely candidate in mechanical load-induced mTOR activation and hypertrophy. Support for this model was based on the capacity for mechanical stimulation to elevate insulin-like growth factor-1 (IGF-1), which has been shown to initiate the PI3K-Akt signalling pathway, resulting in hypertrophy (Rommel et al. 2001) . Indeed, Atherton et al. (2005) demonstrated that high-frequency electrical stimulation of rat muscle phosphorylated PI3K-Akt and mTOR, promoting an enhancement in translational efficiency. These observations rendered the idea that PI3K-AKT activation was indispensable for mechanical loadinduced mTOR signalling and subsequent skeletal muscle growth. However, research utilising a mouse model that harboured an inactivating knockin mutation in the IGF receptor, to prevent receptor activation by insulin or IGF-1, challenged this hypothesis. Specifically, Spangenburg and colleagues (2008) showed that in the absence of IGF-1 signalling, load-induced muscle hypertrophy was identical to that of wild-type mice, although not during the initial 8-week developmental stage. More recently, others have demonstrated that muscle growth can occur in a growth factorindependent manner in humans. West et al. (2010) used a 15-week unilateral resistance exercise program, in which 1 arm performed resistance exercise immediately before heavy lifting with the legs (creating a "high" hormonal milieu), while the other arm was exercised on a separate day without concomitant leg exercise (creating a "low" hormonal milieu). Despite substantial differences in circulating hormone levels between high and low exercise bouts, there was no difference in the increase in muscle fiber size and strength following training. Surprisingly, the mechanisms that underpin mechanical load-induced mTOR activation have remained largely elusive (Goodman 2014; Hornberger 2011) . However, important work by Fang and colleagues (2001) proposed a mechanism of cell growth involving PA. In this study, mitogenic activation of human embryonic kidney 293 cells resulted in an acute increase in cellular PA. Interestingly, PA was able to directly activate mTOR, leading to the preposition that PA and rapamycin directly compete for binding of the FRB domain of mTORC1, reducing the inhibitory capacity of rapamycin on mTOR activity. Since the discovery of Fang et al. (2001) , a growing number of studies suggest a key role for mechanical load-induced endogenous PA production in cell growth (Hornberger et al. 2006; O'Neil et al. 2009; You et al. 2012) .
The primary cellular mechanism responsible for the synthesis of PA in response to mechanical loading was originally understood to be through hydrolysis of PC by the PLD1 and PLD2 isoforms of PLD. In an elegant study from O'Neil et al. (2009) rodents were subjected to eccentric loading to elicit muscle hypertrophy. Whilst PI3K activation in response to eccentric loading was transient (ϳ15 min), the activation of mTOR was sustained (>12 h), suggesting minimal involvement of PI3K in mechanical loadinduced hypertrophy. Alternatively, a key regulatory role was posed for the mechanical load-induced synthesis of PA by PLD. In support of this notion, inhibition of PLD with a primary alcohol (1-butanol) prevents any increase in PA and mTOR activation (Fang et al. 2001; Hornberger et al. 2006; O'Neil et al. 2009 ). Studies utilising 1-butanol implicate a key role for PA in activation of mTOR following mechanical loading, whilst confirming that mechanical activation of mTOR occurs in a PI3K-independent manner. As a note of caution, others have questioned the use of alcohols to block PLD activity. Primary alcohols, such as 1-butanol, block the production of PA by both PLD isoforms through formation of inert phosphatidyl-alcohols instead of PA (Foster 2007) . However, the ability of primary alcohols (i.e., 1-butanol) to block PLD activity may not be entirely specific (Su et al. 2009 ). Consequently, the more specific PLD inhibitor, 5-fluoro-2-indolyl deschlorohalopemide (FIPI), has been used in more recent studies (Su et al. 2009 ). Interestingly, the study of You et al. (2014) , utilising FIPI, demonstrated that mechanical loading increases intracellular PA concentration leading to mTOR phosphorylation, independent of PLD activation. By rendering PLD activation for PA synthesis superfluous, the search for alternative PA synthesising enzymes that increase the mechanical load-induced endogenous PA concentration has continued. Of particular interest are the diacylglycerol kinase (DGK) enzymes, which are a family of lipid kinases that synthesise PA from DAG. The DGK family has multiple members that can be classified into 5 subgroups (I-V) based upon their functional domains (Avila-Flores et al. 2005) . Early evidence established that electrical stimulation of the sciatic nerve of anaesthetised rats, in vivo, results in a 2-fold increase in DAG and PA in the gastrocnemius-plantaris-soleus muscle group (Cleland et al. 1989) , and that mechanical stretch of rat cardiac myocytes ex vivo can increase DAG content (Sadoshima and Izumo 1993) . These findings have been confirmed by You et al. (2014) , who demonstrated a rapid increase in intracellular DAG after mechanical stretch, alongside a biphasic increase in DGK activity. Each DGK isoform has a specific intracellular localisation that may refer to its ability to regulate distinct DAG and PA pools. Based on evidence demonstrating that overexpression of DGK in cells led to a dosedependent phosphorylation of p70S6K, the DGK isoform was hypothesised as a potential candidate for synthesis of PA in response to mechanical stimulation (Avila-Flores et al. 2005 ). These findings have been confirmed by You et al. (2014) , who demonstrated that overexpression of the isoform of DGK in serumdeprived cells results in mTOR-dependent phosphorylation of p70S6K, and that mechanically induced increase in PA and mTOR signalling is impaired in DGK−/− muscles from mice. These results appear to implicate DGK in the mechanical load-induced synthesis of PA and activation of mTORC1 via direct binding of the FRB domain.
To summarise, a role in mechanical activation of mTOR has been implicated for PA. Mechanical loading causes an increase in PLD1 activity that subsequently synthesizes PA. Primary alcohols that inhibit PLD1 synthesis of PA initially supported the importance of PLD1 in the formation of PA and subsequent activation of mTOR in response to mechanical stimuli. However, when using FIPI, a more specific PLD1 inhibitor, the role of PLD1 in mechanical load-induced mTOR activation only appears to be secondary. Alternatively, recent evidence proposes DGK as the primary enzyme responsible for mechanical load-induced rise in PA production and direct mTOR activation through binding of the FRB domain.
Exogenous phosphatidic acid provision
Whilst endogenous PA can directly activate mTOR signalling by binding the FRB domain following various forms of mechanical stimulation, it has also been suggested that exogenous PA can evoke mTOR-mediated signalling, albeit via a mechanism distinct from that through which mechanical stimuli act. In vitro cell culture and in vivo animal studies of the molecular processes through which exogenous PA acts provide useful platforms for investigation of the potential for oral PA supplementation to promote anabolism in human skeletal muscle. PA is found in a number of commonly consumed food sources (Tanaka et al. 2012) , such as cabbage, tomato, and cucumber (ϳ0.55, 0.25, and 0.2 mg/g wet weight, respectively), although the method by which these foods are prepared (i.e., boiling) can reduce the PA content, potentially because of inactivation of PA synthesising enzymes (Tanaka et al. 2012) . Previous in vitro cell culture and in vivo animal studies demonstrate that the presence of exogenous PA enhances mTORmediated signalling (Mobley et al. 2015; Winter et al. 2010; Yoon et al. 2011; You et al. 2012) . This response appears to act through a PI3K-independent mechanism, as provision of exogenous PA to C2C12 myoblasts and PA feeding in rats results in p70S6K but not Akt phosphorylation (Mobley et al. 2015; O'Neil et al. 2009 ). Moreover, Wortmannin administration does not prevent exogenous PA-induced phosphorylation of p70S6K in this same cell model. Accordingly, it appears that exogenous PA induces mTOR-mediated signalling via an alternative mechanism to insulin/growth factors, which activate mTORC1 via a PI3K-dependent mechanism. More precisely, insulin/growth factors bind to the insulin receptor, resulting in autophosphorylation and subsequent docking of insulin receptor substrates 1/2 (Shepherd et al. 1998) . This leads to activation of a series of intracellular events involving PI3K that co-localize Akt and 3-phosphoinositide-dependent protein kinase-1 (PDK1) to the membrane (Alessi and Cohen 1998) , where PDK1 and mTORC2 phosphorylate Akt, resulting in Akt activation (Alessi et al. 1997; Sarbassov et al. 2005) . Activated Akt subsequently phosphorylates and inactivates tuberous sclerosis complex 2 (TSC2) (Inoki et al. 2002) , removing its inhibition of Ras homolog enriched in brain (Rheb). This places Rheb in a guanosine triphosphate (GTP) bound state where it can ultimately evoke mTORC1 activity (Sato et al. 2009 ). Interestingly, unlike insulin/growth factors, both amino acids ) and mechanical loading (Hamilton et al. 2010 ) induce mTORC1-dependent signalling via pathways distinct of PI3K. Instead, amino acids and mechanical loading act through divergent pathways to converge on, and synergistically enhance, mTORC1 activation (Dreyer et al. 2008 ). For example, it has been demonstrated that cells lacking TSC2 remain responsive (i.e., p70S6K phosphorylation remains apparent) to amino acid provision . Instead, it appears amino acids, in contrast to insulin/growth factors and mechanical loading, promote mTORC1 movement to the lysosome for interaction with Rheb, mediated by the Rag GTPases, a family of G-proteins (Sancak et al. 2010) . Based on the premise that exogenous PA, amino acids, and mechanical loading induce mTORC1 signalling through divergent upstream signalling events, there is a distinct possibility that these stimuli act in parallel to synergistically enhance mTOR signalling, MPS, and hypertrophy.
As discussed previously, mechanically induced endogenous PA binds directly to the FRB domain of mTOR, upregulating mTOR kinase activity. However, evidence that exogenously supplied PA also binds directly to FRB domain of mTOR is less conclusive. For example, exogenous PA in vitro increases mTOR kinase activity and p70S6K phosphorylation, whilst disrupting the interaction between FK506 binding protein 38 (FKBP38) and the FRB domain of mTOR (Yoon et al. 2011) . FKBP38, an endogenous inhibitor of mTOR, exerts its effect via binding of the mTOR FRB domain and, as such, it would appear that exogenous PA competes for binding of the mTOR FRB domain, in a manner similar to mechanically induced PA (Yoon et al. 2011) . A caveat to this notion, however, is that exogenous PA does not reverse FKBP38 inhibition of mTORC1 signalling and FKBP38 knockdown fails to prevent additional stimulation of mTORC1 signalling by exogenous PA (Yoon et al. 2011) . Taken together, although exogenous PA may require displacement of FKBP38 from the FRB domain to activate mTORC1, there are alternative mechanisms that trigger exogenous PA activation of mTOR-mediated signalling.
The alternative mechanism through which exogenous PA mediates mTOR activation is thought to involve the extracellularsignal-regulated kinase (ERK). ERK phosphorylation can result in phosphorylation and subsequent inactivation of the tuberous sclerosis complex (TSC1/2) (Ma et al. 2005) , placing Rheb in a GTPbound state where it can directly activate mTORC1. As a result, it has been proposed that exogenous PA promotes mTORC1 signalling via activation of the ERK and PLD signalling pathways (Winter et al. 2010) . As previously mentioned, PA can be converted to LPA via PLA, which consists of 2 main forms: PLA1 and PLA2. PLA1 and PLA2 catalyse the hydrolysis of acyl groups at the sn-1 and sn-2 position of PA, respectively (Aoki et al. 2007; Murakami and Kudo 2002) , resulting in LPA formation. LPA-induced activation of the LPA receptor, the endothelial differentiation gene (EDG-2) receptor, upregulates the ERK and PLD signalling pathways (Xu et al. 2000) . As such, it has been proposed that PLA present in the culture medium hydrolyses PA to LPA, which binds to the EDG-2 receptor and subsequently activates the ERK and PLD, resulting in mTORC1 activation (Winter et al. 2010) . In support of this notion, treatment of serum-deprived cells with exogenous PA fails to promote mTORC1 signalling at 30 and 120 min post-treatment; whereas in cells incubated in a 0.5% serum medium, exogenous PA activates mTORC1 signalling 120 mins post-treatment (Winter et al. 2010 ). This suggests that (i) PLA present in the culture medium is necessary for exogenous PA-induced mTORC1 activation, and (ii) exogenous PA must be hydrolysed to LPA to promote mTORC1 activation. Demonstration that inhibition of the EDG-2 LPA receptor prevents PA-induced mTORC1 activation provides further support for this notion (Winter et al. 2010) . As depicted in Fig. 1 , LPA activation of the EDG-2 receptor results in G-proteinmediated signalling through ERK and PLD and activation of mTORC1. Evidence to support LPA-induced activation of the ERK and PLD pathways is apparent when considering data showing that inhibition of mitogen-activated protein kinase, upstream of ERK and key for its activation, attenuates PA and LPA-induced ERK and p70S6K phosphorylation and that exogenous LPA increases PLD activity in cells (Winter et al. 2010) . The resultant PA synthesised from the hydrolysis of PC by G-protein-mediated PLD can then activate the ERK pathway via binding and subsequent activation of Raf (Rizzo et al. 2000) and may also directly bind and activate mTORC1 (Fig. 1) .
The evidence presented thus far suggests that exogenous PA induces mTORC1 activation primarily via an ERK-dependent mechanism in contrast to the available in vivo data, which suggests direct binding of PA onto the FRB domain of mTOR. On the contrary, it has been suggested that in fact, exogenous PA induces mTORC1 activation via an ERK-independent mechanism (You et al. 2012) . Based on the findings of You et al. (2012) , it would seem that exogenous PA induces mTOR signalling via an ERK-independent mechanism, as the authors demonstrated that inhibition of ERK does not completely prevent exogenous PA-induced p70S6K and 4E-BP1 phosphorylation. However, it is important to consider that ERK inhibition did significantly reduce exogenous PA-induced p70S6K and 4E-BP1 phosphorylation in this study. These data suggest that whilst exogenous PA possesses the ability to induce mTORC1 signalling via an ERK-independent mechanism (i.e., direct binding to the FRB domain of mTOR), exogenous PA primarily induces mTORC1 signalling via an ERK-dependent mechanism. This is further supported by data from the same study indicating that ERK inhibition prevents exogenous PA-induced protein synthesis (You et al. 2012) . Whilst exogenous PA stimulates mTORC1 signalling and potentially MPS, preliminary evidence also indicates that exogenous PA may attenuate MPB. Atrogenes are atrophy-related genes implicated in muscle protein catabolism, and the expression of these genes is often used as a marker of MPB (Bodine et al. 2001b; Wall et al. 2012 ). The addition of exogenous PA to myotubes treated with atrophy-inducing compounds was shown to prevent myotube atrophy and significantly attenuate the expression of factors implicated in muscle proteolysis, including the ubiquitin ligases atrogin-1, and muscle RING finger 1 and the forkhead box O3 transcription factor (Jaafar et al. 2013 ). Thus, it is possible that exogenous PA may possess both pro-anabolic and anti-catabolic properties. If this is the case, then oral PA supplementation represents a potentially effective strategy to simultaneously increase rates of MPS and attenuate rates of MPB. A schematic depicting the divergent pathways by which mechanicalloading and exogenous PA may act to increase mTORC1 signalling is provided in Fig. 1 . Taken together, these findings indicate that both endogenous and exogenous PA can activate mTOR, resulting in increased protein translation efficiency. Whereas endogenous PA achieves mTORC1 stimulation by direct binding onto the FRB domain, exogenous PA is thought to activate mTOR mainly through the ERK pathway. Furthermore, a role might exist for exogenous PA to decrease MPB by attenuating atrogene expression.
Phosphatidic acid and human skeletal muscle hypertrophy
Based on the premise that mechanically induced endogenous PA activates mTORC1 signalling via an ERK-independent mechanism (i.e., direct binding of the mTOR FRB domain) (Hornberger et al. 2006; You et al. 2012 You et al. , 2014 and that exogenous PA activates mTORC1 signalling via an ERK-dependent mechanism (Winter et al. 2010; You et al. 2012) , it has been postulated that oral PA provision and mechanical loading (i.e., resistance exercise) may act synergistically to enhance mTOR-mediated signalling, MPS, and hypertrophy in humans. In theory, it is conceivable that resistance exercise and oral PA provision may activate parallel pathways to converge on mTORC1 (Fig. 1) , thereby heightening phosphorylation/activity, which we speculate may translate to enhancement in MPS rates. Two studies to date have partially attempted to examine this theory. In the first of these studies, young resistance-trained males consumed 750 mg of soy-derived PA or a placebo daily during 8 weeks of whole-body resistance training (Hoffman et al. 2012) . Soy-derived PA has recently been reported to induce greater mTOR activation than egg-derived PA in vitro (Joy et al. 2014 ) and as such, is the current preferred form of orally ingestible PA in humans. Oral PA supplementation did not enhance "gains" in muscle strength or lean body mass (LBM) over the course of training compared with a placebo (Hoffman et al. 2012 ). However, a number of methodological limitations warrant discussion when interpreting these data, including (i) the absence of control over timing of PA ingestion in relation to resistance training, (ii) unsupervised resistance training, and (iii) a small subject sample size (n = 16) that may have masked any potential difference in body composition or strength between PA and placebo. More recently, others have sought to address these limitations. Identical to the previous study, young resistancetrained males consumed 750 mg of soy-derived PA or a placebo daily, whilst completing 8 weeks of whole-body resistance training (Joy et al. 2014) . However, the periodised resistance-training program was performed under supervision, timing of PA ingestion was controlled, and a larger subject cohort completed the study (n = 28). Following training, significantly greater increases in Fig. 1 . Proposed model of endogenous and exogenous phosphatidic acid (PA)-induced activation of mammalian target of rapamycin complex 1 (mTORC1) signalling. Mechanical stimulation, through an unknown mechanoreceptor, results in an increase in endogenous PA synthesis via diacylglycerol kinase zeta (DGK). Endogenous PA then competes with rapamycin/FK506-binding protein 12 (FKBP12) for direct binding of the FKB12 rapamycin-binding (FRB) domain of the mTORC1, resulting in mTORC1 activation. Exogenous PA is hydrolysed to lyso-phosphatidic acid (LPA) via the A type phospholipases. LPA then activates the endothelial differentiation gene (EDG-2) receptor, resulting in G-protein-mediated activation of Ras and subsequent activation the mitogen-activated protein kinase (MEK) -extracellular regulated kinase (ERK) pathway. ERK1/2 then phosphorylates and inhibits the tuberous sclerosis complex (TSC1/2), placing Ras homolog-enriched in brain (Rheb) in its guanosine triphosphate (GTP)-bound state where it can directly activate mTORC1. LPA also induces a G-protein-mediated increase in phospholipase D (PLD) activity, leading to increased synthesis of PA. PA then binds to Raf, consequently activating the MEK-ERK pathway. PA synthesised by G-protein-mediated PLD may also directly bind the FRB domain and activate mTORC1. As a result of activation by endogenous and exogenous PA, mTORC1 phosphorylates its downstream substrates ribosomal S6 kinase 1 (p70S6K) and eukaryotic initiation factor 4E-binding protein (4E-BP1), resulting in increased protein synthesis. Exogenous PA may also reduce protein breakdown via attenuation of forkhead box O3 (FoxO3), atrogin-1, and muscle RING finger 1 (MuRF-1) expression.
whole-body LBM (+1.2 kg vs. placebo), rectus femoris cross-sectional area (+0.4 cm vs. placebo), and whole-body strength (+22 kg vs. placebo) were observed in the PA group compared with placebo. Contrary to the initial study (Hoffman et al. 2012) , these data suggest that oral PA supplementation does augment resistance exerciseinduced skeletal muscle hypertrophy and strength in young males. However, whilst these findings are encouraging, there is a clear need for further in vivo mechanistic studies (i.e., muscle anabolic signalling and protein synthesis) and long-term randomized controlled trials in humans to determine the efficacy of PA as a means to promote muscle anabolism in the context of health and disease. In addition, it is also important to consider that the dose-response of orally ingested PA has not been demonstrated and thus we have yet to discover whether a PA dose >750 mg (the "effective" dose provided in human studies) can further increase circulating and intramuscular PA concentrations and enhance muscle anabolism. A final important point to consider is that whilst mTORC1 activation (i.e., p70S6K phosphorylation) positively correlates with mechanical load-induced MPS, hypertrophy, and strength gains in response to resistance training (Baar and Esser 1999; Mitchell et al. 2013; Terzis et al. 2008) , marginal enhancement of mTOR-mediated signalling activity may not necessarily translate to a demonstrable enhancement in muscle protein synthesis or hypertrophy. In fact, in rodents it has been demonstrated that ϳ30% of the maximal mTORC1 activity is sufficient to fully saturate the ensuing muscle protein synthetic response (Crozier et al. 2005) . Additionally, recent work demonstrated that acute rates of MPS may not necessarily reflect of long-term changes in muscle mass and strength . Consequently, it could be argued that even if oral PA supplementation does act in parallel to mechanical loading and amino acid provision to synergistically enhance mTORC1 activity, this may not necessarily elevate rates of MPS and augment muscle hypertrophy. Put another way, activation of mTOR through mechanical loading and/or amino acid-mediated may sufficiently maximise muscle hypertrophy, even in the face of oral PA provision to 'bolster' mTOR signalling and potentially MPS. The studies of Hoffman et al. (2012) and Joy et al. (2014) provided a mixed collagen protein supplement (typically low in essential amino acids) to participants in an attempt to control/minimize the effect of habitual dietary protein consumption on resistance training-induced muscle hypertrophy. Thus, it appears that oral PA supplementation synergistically enhanced the muscle anabolic response to resistance exercise and collagen protein ingestion in these studies. From this, it seems safe to assume that the low EAA-containing collagen protein and/or resistance exercise stimuli were not sufficient to maximize MPS and hypertrophy. The discrepancy between PA-mediated enhancement of mTOR signalling and muscle protein synthesis is reinforced by recent work from Mobley and colleagues (2015) . In this study, the equivalent of 1.5 g of PA and 10 g of whey protein (WP) was fed to rats alone and in combination. PA + WP resulted in numerically (but not statistically) greater mTOR-mediated signalling than WP and PA alone. Surprisingly, whereas WP, and to a lesser extent PA, elevated muscle protein synthesis rates above control values, PA + WP failed to stimulate muscle protein synthesis, which the authors speculate may have been due to PA + WP-induced alterations in mTOR signalling dynamics, thereby "shifting" the peak muscle protein synthetic response beyond the 3-h window of investigation. This idea that PA might alter anabolic signalling dynamics is yet to be examined in depth, but opens up avenues of exploration for future research.
Potential for therapeutic benefits with phosphatidic acid in "compromised" muscles
Although the potential for oral PA to augment skeletal muscle adaptations to combined resistance training and EAA-enriched protein ingestion in young, healthy individuals cannot be dismissed, oral PA may offer greater potential benefit to anabolically resistant old or cachectic muscles. The mechanisms underpinning anabolic resistance to mechanical loading and protein-based nutrition in older individuals are likely multi-factorial, but appear to manifest in diminished mTORC1-mediated phosphorylation of p70S6K and 4E-BP1 (Cuthbertson et al. 2005; Fry et al. 2011; Kumar et al. 2009 ). As exogenous PA enhances mTOR-mediated signalling in vitro and in vivo (Mobley et al. 2015; Winter et al. 2010; Yoon et al. 2011; You et al. 2012) , and can also bind directly to p70S6K, resulting in heightened enzyme activity (Lehman et al. 2007 ), we postulate that oral PA may possess the anabolic properties to "bolster"' the muscle protein synthetic response in anabolically resistant muscles. Of great interest from a clinical perspective is preliminary in vitro evidence suggesting that exogenous PA may also reduce MPB via attenuation of atrogene expression (Jaafar et al. 2013) . Diseased states such as cancer cachexia, rheumatoid arthritis, and COPD are characterised by a chronic inflammatory state that compromises skeletal muscle NPB through elevated rates of MPB (Rennie 2009 ). As such, the potential for oral PA to restore healthy NPB and offset the trajectory of cachexia cannot be ruled out. Additionally, oral PA supplementation may be valuable in situations of musculoskeletal unloading (i.e., hospitalization or bed rest) or for individuals consuming suboptimal dietary protein (Fulgoni 2008; Keller 1993) to maintain skeletal muscle mass (i.e., due to enteral/parenteral feeds, low socioeconomic status, or blunted olfactory/taste perception). Indeed, it has recently been demonstrated that the addition of leucine to a suboptimal protein dose in young and older individuals can enhance the MPS response Katsanos et al. 2006; Wall et al. 2013) . Furthermore, prolonged supplementation with fish-oil-derived omega-3 fatty acids (n-3 polyunsaturated fatty acids) has been shown to restore the MPS response to nutrient provision (Smith et al. 2011 ) and promote muscle hypertrophy and improved function in older individuals (Smith et al. 2015) , independently of any exercise training stimulus. Accordingly, it could be of interest to explore the possibility of whether oral PA supplementation plays a similar role to leucine and n-3 PUFAs when protein intake is insufficient to maximize postprandial MPS. This suggestion appears plausible as PA and leucine have been shown to synergistically enhance mTORC1 signalling in cells (Winter et al. 2010) . Certainly the proposals presented are speculative and further in vivo human validation trials are required, the importance of which cannot be over emphasised.
Conclusions
In summary, mechanical loading appears to increase DGK synthesis of PA, which subsequently binds directly to the FRB domain of mTOR, increasing mTOR activity. On the other hand, exogenous PA appears to be metabolised to LPA by PLA, which can subsequently bind to the LPA receptor on the cell membrane, resulting in activation of the ERK and PLD pathways and resultantly, increased mTORC1 activity. Whether exogenous PA administration in vitro necessarily replicates oral PA supplementation in vivo remains to be clarified. Similarly, whether greater mTOR activity as a result of PA administration results in greater rates of MPS also remains to be elucidated in vivo. However, future in vivo mechanistic studies will help to shed further light on these matters. Future studies should also attempt to determine (i) the significance of mechanically induced PA to skeletal muscle hypertrophy in vivo in humans; (ii) the digestion and absorption kinetics of graded-dose oral PA at rest and following exercise; and (iii) the synthesis of mechanically induced PA and concentration of orally ingested PA in skeletal muscle cells.
